Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of MIRCERA is substantial. |
Clinical Added Value
| no clinical added value |
MIRCERA offers no improvement in actual benefit (level V) compared to the other
erythropoiesis-stimulating agents that are indicated in the correction of anaemia associated with chronic kidney disease. |
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
XpARBXjXAJFX5qUg
